Ethic Inc. Acquires Shares of 17,036 Kyverna Therapeutics, Inc. $KYTX

Ethic Inc. acquired a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 17,036 shares of the company’s stock, valued at approximately $56,000.

A number of other large investors have also modified their holdings of the stock. Vanguard Personalized Indexing Management LLC raised its holdings in shares of Kyverna Therapeutics by 25.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 19,122 shares of the company’s stock valued at $59,000 after buying an additional 3,847 shares during the period. Bank of America Corp DE grew its position in Kyverna Therapeutics by 41.6% in the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after acquiring an additional 6,400 shares in the last quarter. Rhumbline Advisers grew its position in Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after acquiring an additional 5,694 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Kyverna Therapeutics during the first quarter valued at approximately $92,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Kyverna Therapeutics by 22.2% during the first quarter. Bank of New York Mellon Corp now owns 48,784 shares of the company’s stock worth $94,000 after purchasing an additional 8,851 shares in the last quarter. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Trading Up 3.3%

KYTX stock opened at $6.97 on Friday. The firm has a market cap of $301.45 million, a P/E ratio of -1.89 and a beta of 3.72. Kyverna Therapeutics, Inc. has a 12-month low of $1.78 and a 12-month high of $8.45. The stock’s 50 day simple moving average is $5.60 and its 200 day simple moving average is $3.88.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.03. On average, research analysts forecast that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on KYTX shares. Wells Fargo & Company upped their target price on shares of Kyverna Therapeutics from $27.00 to $31.00 and gave the company an “overweight” rating in a research note on Wednesday. HC Wainwright boosted their price objective on shares of Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Kyverna Therapeutics in a research note on Tuesday, October 14th. Finally, William Blair began coverage on Kyverna Therapeutics in a research note on Wednesday, August 20th. They issued an “outperform” rating on the stock. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.67.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.